Physician profile

William Y Han

Pulmonary Disease · Baltimore, MD

NPI 1558325316

$2,408.57

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $739.00 2019-2021
Astrazeneca Pharmaceuticals LP $563.41 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $323.69 2019-2021
Insmed, INC. $134.00 2019-2021
Veran Medical Technologies, INC. $104.04 2020
Genentech USA, INC. $68.62 2019
Grifols USA, LLC $62.12 2019-2021
Actelion Pharmaceuticals US, INC. $58.87 2019-2020
Genzyme Corporation $42.98 2019-2021
Regeneron Healthcare Solutions, INC. $38.72 2019-2021
Horizon Therapeutics Plc $35.00 2019
Janssen Pharmaceuticals, INC $33.60 2019-2020
Pfizer INC. $31.22 2019
Abbvie INC. $23.97 2021
Gilead Sciences, INC. $22.02 2021
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Sobi, INC $19.36 2019
Sanofi Pasteur INC. $17.67 2020
United Therapeutics Corporation $16.98 2021
Sunovion Pharmaceuticals INC. $16.64 2019
Resmed Corp $16.39 2019
Biomerieux INC $15.61 2019
Inogen, INC. $13.00 2019
Advanced Respiratory, INC $11.66 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William Y Han

$2,408.57

in general payments reported 2019-2025

Years
2019-2021
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/70263/william-y-han

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.